The $294 Billion Peptide Boom: Biotech Companies Positioned for the Next Wave of Growth

Pratap Sandhu, CEO of The Precision Peptide Company

“In July we opened the door with a handful of therapies. Four months later we cover seven therapy areas and 16 prescription therapies, with stacked protocols on top. That is the platform we set out to build: one U.S. company where a customer can start with a needle-free patch, add a daily capsule and move into a clinician-prescribed program, without ever leaving the brand. Breadth is what turns a first purchase into a long-term relationship, and we are not finished adding to it.”

Andrew Dudum, Co-founder and CEO of Hims & Hers Health

“Hims & Hers is delivering a world-class health experience at a global scale and a reasonable price for the nearly 3 million people who rely on us for access to care. We’re proving, quarter after quarter, that helping people feel great and delivering strong results aren’t mutually exclusive.”

Andrew Dudum, Co-founder and CEO of Hims & Hers Health

“We have never been better positioned to move faster or go further than we are today. As we rebuild the consumer health experience from the ground up with a doctor-led AI clinical engine, the depth and breadth of our relationships with customers worldwide has never been greater. Every quarter, we raise the standard for what care should look like everywhere: high-quality, personal, and accessible.”

Yemi Okupe, Chief Financial Officer of Hims & Hers Health

“Our second quarter results were defined by a significant re-acceleration in our growth profile and the continued expanding reach of our platform.”

Yemi Okupe, Chief Financial Officer of Hims & Hers Health

“Domestic revenue growth accelerated to 16% year-over-year, and our international business grew more than 17-fold, strengthened by the close of our Eucalyptus acquisition in June.”

Yemi Okupe, Chief Financial Officer of Hims & Hers Health

“We expect our domestic business to continue accelerating through the second half of the year.”

Yemi Okupe, Chief Financial Officer of Hims & Hers Health

“This momentum, combined with the meaningful efficiencies we're generating from our investments in AI and technology, positions us to make access to high touch, comprehensive care more affordable for our customers while also significantly expanding our reach internationally.”

Yemi Okupe, Chief Financial Officer of Hims & Hers Health

“As a result, we are raising our 2026 revenue outlook and building increased conviction in our 2030 targets of at least $6.5 billion in revenue and $1.3 billion in Adjusted EBITDA.”

Michelle Skinner Moore, PharmD, MBA, interim head of clinical development, medical and regulatory affairs and vice president, medical affairs at Novo

“Many women with obesity or overweight experience weight gain as they move through menopause, and it is important to explore investigational products such as CagriSema across the reproductive lifespan.”

Michelle Skinner Moore, PharmD, MBA, interim head of clinical development, medical and regulatory affairs and vice president, medical affairs at Novo

“CagriSema has the potential to be the first amylin analog and GLP-1 RA combination therapy for weight management, and these REDEFINE 1 data show it was associated with significant weight loss for women with obesity or overweight. These findings add to the body of evidence from the REDEFINE clinical program.”

Kenneth Custer, Ph.D., Executive Vice President and President of Lilly Cardiometabolic Health

“Head-to-head trials show patients and physicians how a potential new medicine compares with treatments that are available and reimbursed today.”

Kenneth Custer, Ph.D., Executive Vice President and President of Lilly Cardiometabolic Health

“In TRANSCEND-T2D-2, the first Phase 3 trial comparing retatrutide with another incretin medicine, retatrutide delivered greater A1C reduction and more than double the weight loss of the highest approved dose of Ozempic for type 2 diabetes.”

Kenneth Custer, Ph.D., Executive Vice President and President of Lilly Cardiometabolic Health

“Based on these results and those from across our Phase 3 program, we believe retatrutide, if approved, could shift the treatment paradigm for people living with type 2 diabetes, obesity and related cardiometabolic conditions.”